High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease

Journal of Clinical Pharmacology

Volumn 51, Issue 7, 2011, Pages 1025-1034

  Xie, Di ^a   Hou, Fan Fan ^a   Fu, Bi Ling ^a   Zhang, Xun ^a   Liang, Min ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Proteinuria; RAS inhibitor; renal insufficiency; renal outcome

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; FUROSEMIDE; LOSARTAN; POTASSIUM; PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHINESE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; OPEN STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BIOLOGICAL MARKERS; CHINA; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; LOSARTAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79958824491     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010377502     Document Type: Article

References (14)

1. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int. 2001 ; 60: 2041-2055
2. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002 ; 136: 604-615 (Pubitemid 34407045)
3. Keane WF, Brenner BM, de ZD, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003 ; 63: 1499-1507 (Pubitemid 36350016)
4. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001 ; 135: 73-87 (Pubitemid 32661190)
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993 ; 329: 1456-1462 (Pubitemid 23335891)
6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860
7. De ZD, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004 ; 65: 2309-2320 (Pubitemid 38670018)
8. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007 ; 18: 1889-1898 (Pubitemid 46870325)
9. Adler SG Textbook of Nephrology. 4 th ed. Massry SG Glassock RJ, ed. Philadelphia, PA: Lippincott Williams & Wilkins ; 2001: 1784-1786.
10. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IGA nephropathy. Am J Kidney Dis. 2001 ; 38: 728-735
11. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001 ; 60: 1131-1140 (Pubitemid 34205814)
12. Mancia G, De BG, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 ; 28: 1462-1536
13. Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IGA nephropathy. J Am Soc Nephrol. 2007 ; 18: 3177-3183 (Pubitemid 350223978)
14. Buter H, Hemmelder MH, Navis G, de Jong PE, de ZD. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998 ; 13: 1682-1685 (Pubitemid 28306794)